Los Angeles-based M&A Healthcare Advisors (MAHA) are now registered agents of Finalis, a broker-dealer regulated by the Financial Industry Regulatory Authority (FINRA). This new development enhances the advisory group’s service offerings in the healthcare industry.
Key Points
- MAHA is an advisory group in healthcare mergers and acquisitions (M&A).
- MAHA is now registered with Finalis, a FINRA-regulated broker-dealer. According to the latter’s LinkedIn, “The Finalis platform supercharges independent investment bankers, placement agents, and M&A advisors globally.”
- MAHA will continue to regard sell-side representation as its core focus, leveraging its new status to help clients raise capital or meet their M&A goals.
- Private placement transactions, debt financing options, restructuring, and guidance on the reinvestment of proceeds are among MAHA’s newly unlocked capabilities.
MAHA’s new status makes the boutique healthcare M&A advisory group even more competitive by broadening its capital-raising capabilities and deal support.
The Data
- MAHA focuses on the healthcare industry’s lower-middle market, supporting companies generating $2 million—$20 million of EBITDA.
- At the beginning of the year, 80% of healthcare executives predicted (in a Bain survey) that their M&A dealmaking would equal or exceed 2023 activities.
- The second quarter of 2024 validated this optimism, with 33 transactions vs. 30 in 2023, according to Leerink Partners.
- Biopharma was the most active healthcare subsector, representing 58% of the deal volume, followed by MedTech.
- July 2024 accounts for nearly 15% of the deal volume thus far in 2024, according to Levin Associates.
Industry Context
The majority of self-guided or poorly represented transactions falter and fail.
Andre Ulloa, Founder and Managing Director of M&A Health Advisors
Healthcare industry M&A deals are marked by rapidly evolving regulations and especially complex financial transactions. By becoming registered agents of a broker-dealer, MAHA gains access to a wider array of tools and resources that can assist the lower-middle market. This transition underscores a significant evolution from traditional M&A advisory to a more robust investment banking framework.